BARDA awards Emergent $31m to pursue improved anthrax vax
This article was originally published in Scrip
Executive Summary
The US Biomedical Advanced Research and Development Authority (BARDA) has awarded Emergent BioSolutions a $31m contract to advance the development of its next-generation anthrax vaccine, NuThrax (AV7909), a modified formulation of BioThrax, which is approved by the FDA and currently is being stockpiled by the US in the event of an anthrax attack.